Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “mab”

86 pharma patents match "mab" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 86
Index total 30,257
Page 3 / 4

Quick answer

This filtered view shows 86 pharmaceutical patents matching "mab" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

86 results for “mab” · 30,257 patents in full index Clear search

  1. US 10716854

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jul 21, 2020 · Expires Jul 16, 2040

    granted

  2. US 10688183

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  3. WO 2020012244

    TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AU MOYEN DE BRAZIKUMAB

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 16, 2020 · Expires Jan 11, 2040

    granted

  4. US 10479830

    Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

    CHEMOMAB LTD. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  5. US 10456390

    Combinations comprising MABA compounds and corticosteroids

    Almirall, S.A. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted

  6. US 10413620

    Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging

    The Regents of the University of Colorado, a Body Corporate · Granted Sep 17, 2019 · Expires Sep 12, 2039

    granted

  7. US 10286071

    Syringe containing stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted

  8. US 10286072

    Methods of manufacturing stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted

  9. US 10246508

    Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

    CHEMOMAB LTD. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  10. US 10207000

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted

  11. US 10195275

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Feb 5, 2019 · Expires Jan 31, 2039

    granted

  12. US 10159733

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  13. US 10159732

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  14. US 10155039

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Dec 18, 2018 · Expires Dec 13, 2038

    granted

  15. US 9861695

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Jan 9, 2018 · Expires Jan 4, 2038

    granted

  16. US 9808525

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Nov 7, 2017 · Expires Nov 2, 2037

    granted

  17. US 9789185

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted

  18. US 9782480

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted

  19. US 9782479

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Oct 10, 2017 · Expires Oct 5, 2037

    granted

  20. US 9770507

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

    granted

  21. US 9757454

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Sep 12, 2017 · Expires Sep 7, 2037

    granted

  22. US 9737600

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted

  23. US 9731008

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted

  24. US 9731009

    Stable aqueous formulations of adalimumab

    Coherus BioSciences, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.